All News

PSA068.jpg

Many with Psoriatic Arthritis Fail to Achieve Minimal Disease Activity

d Jack Cush, MD

Despite the availability of numerous advanced therapies for psoriatic arthritis (PsA), there remains a substantial burden and unmet need for improved therapies, according to a newly published Canadian study.

Read Article
panbx.jpg

Polyarteritis Nodosa: Clinical Features and Outcomes

d Jack Cush, MD

A multinational study of polyarteritis nodosa (PAN) through the international GLOBAL-PAN network shows PAN to be a complex, multisystem disorder with a high risk of relapse and low risk of death (11% at 10 years).

Read Article
CV,risk,MI,heart,cardiac

Excess Cardiovascular Risk in Gout

d Jack Cush, MD

A UK population cohort study has shown that gout carries an increased risk for a wide variety of cardiovascular disorders.

Read Article
Blood labs

Can Biomarkers Improve Cardiovascular Risk Assessments in RA?

d Jack Cush, MD

The TARGET (Treatments Against RA and Effect on FDG PET/CT) trial showed that different treatment strategies equally benefited arterial inflammation (by FDG-PET) in rheumatoid arthritis. A subsequent analysis of these patients showed several candidate biomarkers that may correlate with baseline and treatment‐associated changes in arterial inflammation in patients with RA. 

Read Article
Sinusitis Xray maxillary skull

Sinusitis Linked to 40% Heightened Risk of Rheumatic Disease

d EurekAlert!

The common inflammatory condition sinusitis is linked to a 40% heightened risk of a subsequent diagnosis of rheumatic disease, particularly in the 5 to 10 years preceding the start of symptoms, finds research published in the open access journal RMD Open.

Read Article
Metabolic signature for fibromyalgia? Study of 54 FM & 31 controls w/ Machine learning to identify 13 metabolic markers that predicted FM w/ 79% accuracy; levels of 5-hydroxyindole-3-acetic acid & glutamine correlated w/ fatigue. https://t.co/YAjffGVATG https://t.co/5UWNpDNioT

Links:

Dr. John Cush RheumNow ( View Tweet)
As of 11/23, FDA has approved 44 biosimilars to 14 different reference products. FDA systematic review on biosimilars found no differences in the risk of death, serious adverse events, or treatment discontinuations between the switch and no-switch arms.https://t.co/yVScZnP559 https://t.co/feswD1gJz9

Links:

Dr. John Cush RheumNow ( View Tweet)
In 2023, the FDA approved 956 generic drugs and issued 1,493 complete response letters; an improvement on 2022’s 914 approvals and 1,775 complete response letters. https://t.co/XnpQLbxJCr https://t.co/zzf63G4s2R

Links:

Dr. John Cush RheumNow ( View Tweet)
IBD extraintestinal & joint manifestations - systematic review of 61 studies (13,806 pts) found 8% new joint findings during advanced therapy (no signif difference betw vedolizumab (9%) & ustekinumab (6%). https://t.co/drFAtBG4ZU https://t.co/N8ixHS64HD

Links:

Dr. John Cush RheumNow ( View Tweet)
Mastery of knee arthrocentesis for internal medicine resident Brian D. Jaros, MD, presents his poster at RWCS 2024. https://t.co/xFoEGnj2QH https://t.co/DpW07jJTLf

Links:

Dr. John Cush RheumNow ( View Tweet)
EGPA: Benralizumab (BEN) or Mepolizumab (MEP) A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA. https://t.co/1F8hBCOaFV https://t.co/smTSIY1HA3

Links:

Dr. John Cush RheumNow ( View Tweet)
Behçet’s Syndrome A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches. https://t.co/sLgoCRAavP https://t.co/NibyFpPzmW

Links:

Dr. John Cush RheumNow ( View Tweet)
Neonatal Fc receptor mAb (lowers Igs) development: 2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis 2023 FDA approved rozanolixizumab (Rystiggo) for MG 2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG INTERESTING? https://t.co/Ou9An9EvUK https://t.co/XDDELNAYYD

Links:

Dr. John Cush RheumNow ( View Tweet)

PAPA (pyogenic arthritis, pyoderma gangrenosum & acne) syndrome is a hereditary autoinflammatory Dz caused by dominant mutation in PSTPIP1 (triggers IFN-γ-mediated pyrin induction & IL-18 release; can be Tx by JAK inhibition) https://t.co/fy0MnwDA5U https://t.co/l8n2EwgV0t

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/V6zbCnpfvn https://t.co/igLddGMcoM

Links:

Dr. John Cush RheumNow ( View Tweet)
Norway study 1558 chart-reviewed SLE cases; 797 were new-onset SLE from 1999 to 2017. During this period the annual SLE incidence rates fell; mostly pronounced in women 50-59 yrs (fell 3.4 to 1.1 per 100K) - paralleled by 74% reduction menopausal HRT https://t.co/zYkXAnEcOI https://t.co/oaz9t65zZy

Links:

Dr. John Cush RheumNow ( View Tweet)
Australian study shows self-reported difficulties w/ ambulation (limited<=1 km) had a higher risk of hip and spinal fractures (32% to 219% more)/ Included 239 000 adults >45 yrs https://t.co/IWvKmPc2t8 https://t.co/CDYDzhMUoa

Links:

Dr. John Cush RheumNow ( View Tweet)
When Meningitis Strikes Twice Amanda Moyer, MD, presents her poster at RWCS 2024. https://t.co/er2E2XnrZZ https://t.co/vwDopOLPRH

Links:

Dr. John Cush RheumNow ( View Tweet)
With New Medications Come New Myopathies Alexia Hwang, MD, presents her poster at RWCS 2024. https://t.co/BjYxKk2QlW https://t.co/vDA0dllMQz

Links:

Dr. John Cush RheumNow ( View Tweet)
Immunosuppression Increasing Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on https://t.co/V10S4oVFsv; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients. https://t.co/KvZIiKowox https://t.co/cbBYydVQbB

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×